Visual Loss Induced by Adalimumab Used for Plaque Psoriasis

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

OBJECTIVES To investigate the extent antibodies to adalimumab are formed in patients with plaque psoriasis and whether these antibodies have clinical consequences. Also, to examine the relationship between antibodies to adalimumab and adalimumab trough titers. DESIGN Prospective observational cohort study. SETTING Two Dutch dermatology departments in university hospitals. PATIENTS All con...

First Case Report of Aseptic Meningitis Induced by Adalimumab Administered for Treatment of Chronic Plaque Psoriasis.

Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature

Psoriasis is a chronic T-cell-mediated inflammatory disease that primarily affects the skin and joints. Patients with moderate to severe psoriasis constitute about 30% of the psoriasis population. Treatment of this group is challenging due to the long-term side effects, toxicities and inconvenience of conventional treatments such as phototherapy, methotrexate and cyclosporine. However, recent a...

Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.

BACKGROUND In elderly patients the management of psoriasis is challenging due to contraindications and a higher risk of side effects. OBJECTIVE Our retrospective study aimed to evaluate the long-term efficacy and safety profile of subcutaneous anti-tumor necrosis factor (anti-TNF) agents in elderly psoriatic patients. METHODS The study included 89 patients (aged ≥65 years) with plaque-type ...

Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH

BACKGROUND The Randomized Controlled Evaluation of Adalimumab in Treatment of Chronic Plaque Psoriasis of the Hands and Feet (REACH) trial demonstrated that adalimumab was efficacious and well-tolerated for the treatment of hand and/or foot psoriasis through 28 weeks. OBJECTIVE To evaluate the effects of patient baseline characteristics on efficacy of adalimumab treatment of hand and/or foot ...